Key facts
- This page summarizes Garo H. Armen's Form 4/A - Amendment filing for MiNK Therapeutics, Inc. (INKT).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2023, 17:29.
Garo H. Armen - 05 May 2023 Form 4/A - Amendment Insider Report for MiNK Therapeutics, Inc. (INKT)
- Reporting relationship
- Director
- Issuer ticker
- INKT
- Reported as of
- 05 May 2023
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 26 May 2023, 17:29:02 UTC
- Original report date
- 05 May 2023
- Prior SEC filing
- 04 May 2023
- Next SEC filing
- 11 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Christine Klaskin, Attorney-in-Fact for Garo H. Armen
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Garo H. Armen filed Form 4/A - Amendment for MiNK Therapeutics, Inc. (INKT) on 26 May 2023.
Change
- Previous filing in this sequence was filed on 04 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INKT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,966,400
- Date
- 05 May 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction.